バイオ医薬品委託製造の世界市場分析

Future Market Insightsが発行した調査報告書(FUMI712120)
◆英語タイトル:Biopharmaceutical Contract Manufacturing Market: Oncology Segment by Therapeutic Area to Dominate the Global Market Through 2027: Global Industry Analysis 2012–2016 and Opportunity Assessment 2017–2027
◆商品コード:FUMI712120
◆発行会社(リサーチ会社):Future Market Insights
◆発行日:2017年9月6日
◆ページ数:335
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:Healthcare, Pharmaceuticals and Medical devices
◆販売価格オプション(消費税別)
Individual Price(1名様閲覧用)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
Corporate Price(同一法人内共有可)USD7,500 ⇒換算¥847,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はFuture Market Insights社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Future Market Insights社の概要及び新刊レポートはこちらでご確認いただけます。

※本調査レポートでは、バイオ医薬品委託製造の世界市場について調査・分析し、以下の構成でお届けいたします。
・バイオ医薬品委託製造の世界市場概観
・バイオ医薬品委託製造の世界市場規模
・バイオ医薬品委託製造の世界市場予測
・バイオ医薬品委託製造の世界市場:地域別市場分析
・バイオ医薬品委託製造のアメリカ市場規模
・バイオ医薬品委託製造のヨーロッパ市場規模
・バイオ医薬品委託製造のアジア市場規模
・バイオ医薬品委託製造の世界市場:セグメント別市場分析
・バイオ医薬品委託製造の世界市場:競争状況
・バイオ医薬品委託製造の世界市場:市場動向
・バイオ医薬品委託製造の世界市場:関連企業分析
【レポートの概要】

Future Market Insights presents a detailed forecast of the global biopharmaceutical contract manufacturing market in a new report titled “Biopharmaceutical Contract Manufacturing Market: Global Industry Analysis 2012–2016 and Opportunity Assessment 2017–2027” and provides vital insights into the various factors influencing the market currently and over the next 10 years. The report dives deep into the various aspects of the global biopharmaceutical contract manufacturing market and analyses the various market segments and their performance over the forecast period 2017 – 2027. A historical analysis for the period 2012 – 2026 serves as a point of reference in estimating the market forecast for the projected 10 year period starting 2017.

A cohesive report structure that facilitates ease of navigation

The report begins with a succinct executive summary that captures the market overview, market analysis, and our recommendations to key market players. The market introduction describes the global biopharmaceutical contract manufacturing market and highlights the market segmentation. In another section, we present the market viewpoint analysis where we describe the macroeconomic factors impacting revenue growth, opportunity analysis, and the regulatory scenario in the global biopharmaceutical contract manufacturing market.

The subsequent sections provide the regional biopharmaceutical contract manufacturing market forecasts for each of the assessed regions. Here we outline the regional market dynamics (drivers, restraints, trends), historical and projected market forecasts for the various market segments and countries, market attractiveness analysis, key representative market participants, and a market presence intensity map. At the end of these sections is a small chapter on the relevance and impact of the various forecast factors on the global biopharmaceutical contract manufacturing market followed by Future Market Insights forecast assumptions.

A very important section of the report focusses on the competition landscape of the global biopharmaceutical contract manufacturing market. This section is intended to provide a dashboard view of the different companies operating in the global biopharmaceutical contract manufacturing market. We provide useful information such as company overview, key financials, business and marketing strategies, a comprehensive SWOT analysis, and recent market developments. We have also profiled the top companies in the global biopharmaceutical contract manufacturing market to enable our readers to acquire a bird’s eye view of the vendor ecosystem of the global biopharmaceutical contract manufacturing market.

The last section provides the numbers pertaining to the global biopharmaceutical contract manufacturing market revenue along with a global market attractiveness analysis for the various segments across the different regional markets. We also present figures pertaining to the market size, Y-o-Y growth, and absolute $ opportunity; as well as the global biopharmaceutical contract manufacturing market value chain.

Global Biopharmaceutical Contract Manufacturing Market: Segmentation

By Platform

By Application

By Product Type

By Therapeutic Area

By Region

Mammalian

Microbial

Clinical

Commercial

Growth Factors

Interferons

Monoclonal Antibodies

Recombinant Hormones

Vaccines

Insulin

Others

Autoimmune Diseases

Oncology

Metabolic Diseases

Ophthalmology

Cardiovascular Diseases

Infectious Diseases

Neurology

Respiratory Disorders

Others

North America

Latin America

Western Europe

Eastern Europe

Asia Pacific excluding Japan

Japan

Middle East & Africa

A multi-pronged approach to the research to ensure near 100% data accuracy

Future Market Insights deploys a systematic research methodology that is at par with the best in the industry to derive the market estimations for the global biopharmaceutical contract manufacturing market over the forecast period. We begin with market profiling (systematic secondary research that helps us analyse the required data points to arrive at the overall market numbers), developing a list of respondents across the global biopharmaceutical contract manufacturing market value chain and a detailed discussion guide for primary research, data collection (exhaustive primary interviews using distinguished essential resources), data validation using the triangulation method (wherein secondary, primary and our in-depth market analysis contribute to the final data), and finally a comprehensive data analysis and scrutiny using advanced tools to obtain pertinent insights into the global biopharmaceutical contract manufacturing market.

【レポートの目次】

Table Of Content

1. Executive Summary

1.1. Overview

1.2. Market Analysis

1.3. FMI Analysis and Recommendations

1.4. Wheel of Fortune

2. Market Introduction

2.1. Market Taxonomy

2.2. Market Definition

3. Biopharmaceutical Contract Manufacturing Market View Point Analysis

3.1. Macro-Economic Factors

3.2. Opportunity Analysis

3.3. Regulatory Scenario

4. North America Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027

4.1. Introduction

4.2. Regional Market Dynamics

4.2.1. Drivers

4.2.2. Restraints

4.2.3. Trends

4.3. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016

4.3.1. U.S.

4.3.2. Canada

4.4. Market Size (US$ Mn) Forecast By Country, 2017–2027

4.4.1. U.S.

4.4.2. Canada

4.5. Historical Market Size (US$ Mn) By Platform, 2012-2016

4.5.1. Mammalian-based

4.5.2. Microbial-based

4.6. Market Size (US$ Mn) Forecast By Platform, 2017-2027

4.6.1. Mammalian-based

4.6.2. Microbial-based

4.7. Historical Market Size (US$ Mn) By Product Type, 2012-2016

4.7.1. Monoclonal Antibodies

4.7.2. Recombinant Proteins

4.7.3. Vaccines

4.7.4. Insulin

4.7.5. Interferons

4.7.6. Growth Factors

4.7.7. Others

4.8. Market Size (US$ Mn) Forecast By Product Type, 2017-2027

4.8.1. Monoclonal Antibodies

4.8.2. Recombinant Proteins

4.8.3. Vaccines

4.8.4. Insulin

4.8.5. Interferons

4.8.6. Growth Factors

4.8.7. Others

4.9. Historical Market Size (US$ Mn) By Application, 2012-2016

4.9.1. Clinical

4.9.2. Commercial

4.10. Market Size (US$ Mn) Forecast By Application, 2017-2027

4.10.1. Clinical

4.10.2. Commercial

4.11. Historical Market Size (US$ Mn) By Therapeutic Area, 2012-2016

4.11.1. Autoimmune Disease

4.11.2. Oncology

4.11.3. Metabolic Disease

4.11.4. Opthalmology

4.11.5. Cardiovascular Disease

4.11.6. Infectious Disease

4.11.7. Neurology

4.11.8. Respiratory Disorder

4.11.9. Others

4.12. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017-2027

4.12.1. Autoimmune Disease

4.12.2. Oncology

4.12.3. Metabolic Disease

4.12.4. Opthalmology

4.12.5. Cardiovascular Disease

4.12.6. Infectious Disease

4.12.7. Neurology

4.12.8. Respiratory Disorder

4.12.9. Others

4.13. Market Attractiveness Analysis

4.13.1. By Country

4.13.2. By Platform

4.13.3. By Product Type

4.13.4. By Application

4.13.5. By Therapeutic Area

4.14. Key Representative Market Participants

4.15. Market Presence (Intensity Map)

5. Latin America Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027

5.1. Introduction

5.2. Regional Market Dynamics

5.2.1. Drivers

5.2.2. Restraints

5.2.3. Trends

5.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016

5.3.1. Brazil

5.3.2. Mexico

5.3.3. Rest of Latin America

5.4. Market Size (US$ Mn) Forecast By Country, 2017–2027

5.4.1. Brazil

5.4.2. Mexico

5.4.3. Rest of Latin America

5.5. Historical Market Size (US$ Mn) By Platform, 2012-2016

5.5.1. Mammalian-based

5.5.2. Microbial-based

5.6. Market Size (US$ Mn) Forecast By Platform, 2017-2027

5.6.1. Mammalian-based

5.6.2. Microbial-based

5.7. Historical Market Size (US$ Mn) By Product Type, 2012-2016

5.7.1. Monoclonal Antibodies

5.7.2. Recombinant Proteins

5.7.3. Vaccines

5.7.4. Insulin

5.7.5. Interferons

5.7.6. Growth Factors

5.7.7. Others

5.8. Market Size (US$ Mn) Forecast By Product Type, 2017-2027

5.8.1. Monoclonal Antibodies

5.8.2. Recombinant Proteins

5.8.3. Vaccines

5.8.4. Insulin

5.8.5. Interferons

5.8.6. Growth Factors

5.8.7. Others

5.9. Historical Market Size (US$ Mn) By Application, 2012-2016

5.9.1. Clinical

5.9.2. Commercial

5.10. Market Size (US$ Mn) Forecast By Application, 2017-2027

5.10.1. Clinical

5.10.2. Commercial

5.11. Historical Market Size (US$ Mn) By Therapeutic Area, 2012-2016

5.11.1. Autoimmune Disease

5.11.2. Oncology

5.11.3. Metabolic Disease

5.11.4. Opthalmology

5.11.5. Cardiovascular Disease

5.11.6. Infectious Disease

5.11.7. Neurology

5.11.8. Respiratory Disorder

5.11.9. Others

5.12. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017-2027

5.12.1. Autoimmune Disease

5.12.2. Oncology

5.12.3. Metabolic Disease

5.12.4. Opthalmology

5.12.5. Cardiovascular Disease

5.12.6. Infectious Disease

5.12.7. Neurology

5.12.8. Respiratory Disorder

5.12.9. Others

5.13. Market Attractiveness Analysis

5.13.1. By Country

5.13.2. By Platform

5.13.3. By Product Type

5.13.4. By Application

5.13.5. By Therapeutic Area

5.14. Key Representative Market Participants

5.15. Market Presence (Intensity Map)

6. Western Europe Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027

6.1. Introduction

6.2. Regional Market Dynamics

6.2.1. Drivers

6.2.2. Restraints

6.2.3. Trends

6.3. Historical Market Size (US$ Mn) Trend Analysis By Country, 2012–2016

6.3.1. Germany

6.3.2. Italy

6.3.3. France

6.3.4. Spain

6.3.5. U.K.

6.3.6. BENELUX

6.3.7. Nordic

6.3.8. Rest of Western Europe

6.4. Market Size (US$ Mn) Forecast By Country, 2017–2027

6.4.1. Germany

6.4.2. Italy

6.4.3. France

6.4.4. Spain

6.4.5. U.K.

6.4.6. BENELUX

6.4.7. Nordic

6.4.8. Rest of Western Europe

6.5. Historical Market Size (US$ Mn) By Platform, 2012-2016

6.5.1. Mammalian-based

6.5.2. Microbial-based

6.6. Market Size (US$ Mn) Forecast By Platform, 2017-2027

6.6.1. Mammalian-based

6.6.2. Microbial-based

6.7. Historical Market Size (US$ Mn) By Product Type, 2012-2016

6.7.1. Monoclonal Antibodies

6.7.2. Recombinant Proteins

6.7.3. Vaccines

6.7.4. Insulin

6.7.5. Interferons

6.7.6. Growth Factors

6.7.7. Others

6.8. Market Size (US$ Mn) Forecast By Product Type, 2017-2027

6.8.1. Monoclonal Antibodies

6.8.2. Recombinant Proteins

6.8.3. Vaccines

6.8.4. Insulin

6.8.5. Interferons

6.8.6. Growth Factors

6.8.7. Others

6.9. Historical Market Size (US$ Mn) By Application, 2012-2016

6.9.1. Clinical

6.9.2. Commercial

6.10. Market Size (US$ Mn) Forecast By Application, 2017-2027

6.10.1. Clinical

6.10.2. Commercial

6.11. Historical Market Size (US$ Mn) By Therapeutic Area, 2012-2016

6.11.1. Autoimmune Disease

6.11.2. Oncology

6.11.3. Metabolic Disease

6.11.4. Opthalmology

6.11.5. Cardiovascular Disease

6.11.6. Infectious Disease

6.11.7. Neurology

6.11.8. Respiratory Disorder

6.11.9. Others

6.12. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017-2027

6.12.1. Autoimmune Disease

6.12.2. Oncology

6.12.3. Metabolic Disease

6.12.4. Opthalmology

6.12.5. Cardiovascular Disease

6.12.6. Infectious Disease

6.12.7. Neurology

6.12.8. Respiratory Disorder

6.12.9. Others

6.13. Market Attractiveness Analysis

6.13.1. By Country

6.13.2. By Platform

6.13.3. By Product Type

6.13.4. By Application

6.13.5. By Therapeutic Area

6.14. Key Representative Market Participants

6.15. Market Presence (Intensity Map)

7. Eastern Europe Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027

7.1. Introduction

7.2. Regional Market Dynamics

7.2.1. Drivers

7.2.2. Restraints

7.2.3. Trends

7.3. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016

7.3.1. Russia

7.3.2. Poland

7.3.3. Rest of Eastern Europe

7.4. Market Size (US$ Mn) Forecast By Country, 2017–2027

7.4.1. Russia

7.4.2. Poland

7.4.3. Rest of Eastern Europe

7.5. Historical Market Size (US$ Mn) By Platform, 2012-2016

7.5.1. Mammalian-based

7.5.2. Microbial-based

7.6. Market Size (US$ Mn) Forecast By Platform, 2017-2027

7.6.1. Mammalian-based

7.6.2. Microbial-based

7.7. Historical Market Size (US$ Mn) By Product Type, 2012-2016

7.7.1. Monoclonal Antibodies

7.7.2. Recombinant Proteins

7.7.3. Vaccines

7.7.4. Insulin

7.7.5. Interferons

7.7.6. Growth Factors

7.7.7. Others

7.8. Market Size (US$ Mn) Forecast By Product Type, 2017-2027

7.8.1. Monoclonal Antibodies

7.8.2. Recombinant Proteins

7.8.3. Vaccines

7.8.4. Insulin

7.8.5. Interferons

7.8.6. Growth Factors

7.8.7. Others

7.9. Historical Market Size (US$ Mn) By Application, 2012-2016

7.9.1. Clinical

7.9.2. Commercial

7.10. Market Size (US$ Mn) Forecast By Application, 2017-2027

7.10.1. Clinical

7.10.2. Commercial

7.11. Historical Market Size (US$ Mn) By Therapeutic Area, 2012-2016

7.11.1. Autoimmune Disease

7.11.2. Oncology

7.11.3. Metabolic Disease

7.11.4. Opthalmology

7.11.5. Cardiovascular Disease

7.11.6. Infectious Disease

7.11.7. Neurology

7.11.8. Respiratory Disorder

7.11.9. Others

7.12. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017-2027

7.12.1. Autoimmune Disease

7.12.2. Oncology

7.12.3. Metabolic Disease

7.12.4. Opthalmology

7.12.5. Cardiovascular Disease

7.12.6. Infectious Disease

7.12.7. Neurology

7.12.8. Respiratory Disorder

7.12.9. Others

7.13. Market Attractiveness Analysis

7.13.1. By Country

7.13.2. By Platform

7.13.3. By Product Type

7.13.4. By Application

7.13.5. By Therapeutic Area

7.14. Key Representative Market Participants

7.15. Market Presence (Intensity Map)

8. Asia Pacific excluding Japan Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027

8.1. Introduction

8.2. Regional Market Dynamics

8.2.1. Drivers

8.2.2. Restraints

8.2.3. Trends

8.3. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016

8.3.1. China

8.3.2. India

8.3.3. Australia and New Zealand

8.3.4. ASEAN

8.3.5. South Korea

8.3.6. Rest of APEJ

8.4. Market Size (US$ Mn) Forecast By Country, 2017–2027

8.4.1. China

8.4.2. India

8.4.3. Australia and New Zealand

8.4.4. ASEAN

8.4.5. South Korea

8.4.6. Rest of APEJ

8.5. Historical Market Size (US$ Mn) By Platform, 2012-2016

8.5.1. Mammalian-based

8.5.2. Microbial-based

8.6. Market Size (US$ Mn) Forecast By Platform, 2017-2027

8.6.1. Mammalian-based

8.6.2. Microbial-based

8.7. Historical Market Size (US$ Mn) By Product Type, 2012-2016

8.7.1. Monoclonal Antibodies

8.7.2. Recombinant Proteins

8.7.3. Vaccines

8.7.4. Insulin

8.7.5. Interferons

8.7.6. Growth Factors

8.7.7. Others

8.8. Market Size (US$ Mn) Forecast By Product Type, 2017-2027

8.8.1. Monoclonal Antibodies

8.8.2. Recombinant Proteins

8.8.3. Vaccines

8.8.4. Insulin

8.8.5. Interferons

8.8.6. Growth Factors

8.8.7. Others

8.9. Historical Market Size (US$ Mn) By Application, 2012-2016

8.9.1. Clinical

8.9.2. Commercial

8.10. Market Size (US$ Mn) Forecast By Application, 2017-2027

8.10.1. Clinical

8.10.2. Commercial

8.11. Historical Market Size (US$ Mn) By Therapeutic Area, 2012-2016

8.11.1. Autoimmune Disease

8.11.2. Oncology

8.11.3. Metabolic Disease

8.11.4. Opthalmology

8.11.5. Cardiovascular Disease

8.11.6. Infectious Disease

8.11.7. Neurology

8.11.8. Respiratory Disorder

8.11.9. Others

8.12. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017-2027

8.12.1. Autoimmune Disease

8.12.2. Oncology

8.12.3. Metabolic Disease

8.12.4. Opthalmology

8.12.5. Cardiovascular Disease

8.12.6. Infectious Disease

8.12.7. Neurology

8.12.8. Respiratory Disorder

8.12.9. Others

8.13. Market Attractiveness Analysis

8.13.1. By Country

8.13.2. By Platform

8.13.3. By Product Type

8.13.4. By Application

8.13.5. By Therapeutic Area

8.14. Key Representative Market Participants

8.15. Market Presence (Intensity Map)

9. Japan Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027

9.1. Introduction

9.2. Regional Market Dynamics

9.2.1. Drivers

9.2.2. Restraints

9.2.3. Trends

9.3. Historical Market Size (US$ Mn) By Platform, 2012-2016

9.3.1. Mammalian-based

9.3.2. Microbial-based

9.4. Market Size (US$ Mn) Forecast By Platform, 2017-2027

9.4.1. Mammalian-based

9.4.2. Microbial-based

9.5. Historical Market Size (US$ Mn) By Product Type, 2012-2016

9.5.1. Monoclonal Antibodies

9.5.2. Recombinant Proteins

9.5.3. Vaccines

9.5.4. Insulin

9.5.5. Interferons

9.5.6. Growth Factors

9.5.7. Others

9.6. Market Size (US$ Mn) Forecast By Product Type, 2017-2027

9.6.1. Monoclonal Antibodies

9.6.2. Recombinant Proteins

9.6.3. Vaccines

9.6.4. Insulin

9.6.5. Interferons

9.6.6. Growth Factors

9.6.7. Others

9.7. Historical Market Size (US$ Mn) By Application, 2012-2016

9.7.1. Clinical

9.7.2. Commercial

9.8. Market Size (US$ Mn) Forecast By Application, 2017-2027

9.8.1. Clinical

9.8.2. Commercial

9.9. Historical Market Size (US$ Mn) By Therapeutic Area, 2012-2016

9.9.1. Autoimmune Disease

9.9.2. Oncology

9.9.3. Metabolic Disease

9.9.4. Opthalmology

9.9.5. Cardiovascular Disease

9.9.6. Infectious Disease

9.9.7. Neurology

9.9.8. Respiratory Disorder

9.9.9. Others

9.10. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017-2027

9.10.1. Autoimmune Disease

9.10.2. Oncology

9.10.3. Metabolic Disease

9.10.4. Opthalmology

9.10.5. Cardiovascular Disease

9.10.6. Infectious Disease

9.10.7. Neurology

9.10.8. Respiratory Disorder

9.10.9. Others

9.11. Market Attractiveness Analysis

9.11.1. By Platform

9.11.2. By Product Type

9.11.3. By Application

9.11.4. By Therapeutic Area

9.12. Key Representative Market Participants

9.13. Market Presence (Intensity Map)

10. Middle East & Africa Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027

10.1. Introduction

10.2. Regional Market Dynamics

10.2.1. Drivers

10.2.2. Restraints

10.2.3. Trends

10.3. Historical Market Size (US$ Mn) Analysis By Country, 2012–2016

10.3.1. GCC Countries

10.3.2. Turkey

10.3.3. North Africa

10.3.4. South Africa

10.3.5. Rest of MEA

10.4. Market Size (US$ Mn) Forecast By Country, 2017–2027

10.4.1. GCC Countries

10.4.2. Turkey

10.4.3. North Africa

10.4.4. South Africa

10.4.5. Rest of MEA

10.5. Historical Market Size (US$ Mn) By Platform, 2012-2016

10.5.1. Mammalian-based

10.5.2. Microbial-based

10.6. Market Size (US$ Mn) Forecast By Platform, 2017-2027

10.6.1. Mammalian-based

10.6.2. Microbial-based

10.7. Historical Market Size (US$ Mn) By Product Type, 2012-2016

10.7.1. Monoclonal Antibodies

10.7.2. Recombinant Proteins

10.7.3. Vaccines

10.7.4. Insulin

10.7.5. Interferons

10.7.6. Growth Factors

10.7.7. Others

10.8. Market Size (US$ Mn) Forecast By Product Type, 2017-2027

10.8.1. Monoclonal Antibodies

10.8.2. Recombinant Proteins

10.8.3. Vaccines

10.8.4. Insulin

10.8.5. Interferons

10.8.6. Growth Factors

10.8.7. Others

10.9. Historical Market Size (US$ Mn) By Application, 2012-2016

10.9.1. Clinical

10.9.2. Commercial

10.10. Market Size (US$ Mn) Forecast By Application, 2017-2027

10.10.1. Clinical

10.10.2. Commercial

10.11. Historical Market Size (US$ Mn) By Therapeutic Area, 2012-2016

10.11.1. Autoimmune Disease

10.11.2. Oncology

10.11.3. Metabolic Disease

10.11.4. Opthalmology

10.11.5. Cardiovascular Disease

10.11.6. Infectious Disease

10.11.7. Neurology

10.11.8. Respiratory Disorder

10.11.9. Others

10.12. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017-2027

10.12.1. Autoimmune Disease

10.12.2. Oncology

10.12.3. Metabolic Disease

10.12.4. Opthalmology

10.12.5. Cardiovascular Disease

10.12.6. Infectious Disease

10.12.7. Neurology

10.12.8. Respiratory Disorder

10.12.9. Others

10.13. Market Attractiveness Analysis

10.13.1. By Country

10.13.2. By Platform

10.13.3. By Product Type

10.13.4. By Application

10.13.5. By Therapeutic Area

10.14. Key Representative Market Participants

10.15. Market Presence (Intensity Map)

11. Forecast Factors: Relevance and Impact

12. Forecast Assumptions

13. Competition Landscape

13.1. Competition Dashboard

13.2. Company Profiles (Details – Overview, Financials, Strategy, SWOT, Recent Developments)

13.2.1. Lonza Group AG

13.2.2. Baxter Biopharma Solutions

13.2.3. Samsung Biologics Co., Ltd.

13.2.4. Fujifilm Diosynth Biotechnologies

13.2.5. Boehringer Ingelheim GmbH

13.2.6. Patheon N.V.

13.2.7. Rentschler Biotechnologie GmbH

13.2.8. Biomeva GmbH

13.2.9. Probiogen AG

13.2.10. Cytovance Biologics, Inc.

13.2.11. KBI Biopharma, Inc.

13.2.12. WuXi Biologics

13.2.13. Abzena Plc

13.2.14. Vetter Pharma International GmbH

13.2.15. Sandoz International GmbH

13.2.16. Catalent, Inc.

13.2.17. AbbVie Contract Manufacturing (An AbbVie Company)

13.2.18. Ajinomoto Althea, Inc.

14. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027, By Region

14.1. Introduction/Key Findings

14.2. Historical Market Size (US$ Mn) Analysis By Region, 2012–2016

14.2.1. North America

14.2.2. Latin America

14.2.3. Western Europe

14.2.4. Eastern Europe

14.2.5. Asia Pacific excluding Japan

14.2.6. Japan

14.2.7. Middle East & Africa

14.3. Market Size (US$ Mn) Forecast By Region, 2017–2027

14.3.1. North America

14.3.2. Latin America

14.3.3. Western Europe

14.3.4. Eastern Europe

14.3.5. Asia Pacific excluding Japan

14.3.6. Japan

14.3.7. Middle East & Africa

14.4. Market Attractiveness Analysis By Region

15. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027, By Platform

15.1. Introduction/Key Findings

15.2. Historical Market Size (US$ Mn) Analysis By Platform, 2012–2016

15.2.1. Mammalian-based

15.2.2. Microbial-based

15.3. Market Size (US$ Mn) Forecast By Platform, 2017–2027

15.3.1. Mammalian-based

15.3.2. Microbial-based

15.4. Market Attractiveness Analysis By Platform

16. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027, By Product Type

16.1. Introduction/Key Findings

16.2. Historical Market Size (US$ Mn) Analysis By Product Type, 2012–2016

16.2.1. Monoclonal Antibodies

16.2.2. Recombinant Proteins

16.2.3. Vaccines

16.2.4. Insulin

16.2.5. Interferons

16.2.6. Growth Factors

16.2.7. Others

16.3. Market Size (US$ Mn) Forecast By Product Type, 2017–2027

16.3.1. Monoclonal Antibodies

16.3.2. Recombinant Proteins

16.3.3. Vaccines

16.3.4. Insulin

16.3.5. Interferons

16.3.6. Growth Factors

16.3.7. Others

16.4. Market Attractiveness Analysis By Product Type

17. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027, By Application

17.1. Introduction/Key Findings

17.2. Historical Market Size (US$ Mn) Analysis By Application, 2012–2016

17.2.1. Clinical

17.2.2. Commercial

17.3. Market Size (US$ Mn) Forecast By Application, 2017–2027

17.3.1. Clinical

17.3.2. Commercial

17.4. Market Attractiveness Analysis By Application

18. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

18.1. Introduction/Key Findings

18.2. Historical Market Size (US$ Mn) Analysis By Therapeutic Area, 2012–2016

18.2.1. Autoimmune Disease

18.2.2. Oncology

18.2.3. Metabolic Disease

18.2.4. Opthalmology

18.2.5. Cardiovascular Disease

18.2.6. Infectious Disease

18.2.7. Neurology

18.2.8. Respiratory Disorder

18.2.9. Others

18.3. Market Size (US$ Mn) Forecast By Therapeutic Area, 2017–2027

18.3.1. Autoimmune Disease

18.3.2. Oncology

18.3.3. Metabolic Disease

18.3.4. Opthalmology

18.3.5. Cardiovascular Disease

18.3.6. Infectious Disease

18.3.7. Neurology

18.3.8. Respiratory Disorder

18.3.9. Others

18.4. Market Attractiveness Analysis By Therapeutic Area

19. Global Biopharmaceutical Contract Manufacturing Market Analysis 2012–2016 and Forecast 2017–2027

19.1. Market Size and Y-o-Y Growth

19.2. Absolute $ Opportunity

19.3. Market Value Chain

List of Tables

Table 01: North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 02: North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Platform

Table 03: North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Product Type

Table 04: North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Application

Table 05: North America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

Table 06: Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 07: Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Platform

Table 08: Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Product Type

Table 09: Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Application

Table 10: Latin America Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

Table 11: Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 12: Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Platform

Table 13: Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Product Type

Table 14: Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Application

Table 15: Western Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

Table 16: Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 17: Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Platform

Table 18: Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Product Type

Table 19: Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Application

Table 20: Eastern Europe Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

Table 21: APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 22: APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Platform

Table 23: APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Product Type

Table 24: APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Application

Table 25: APEJ Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

Table 26: Japan Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Platform

Table 27: Japan Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Product Type

Table 28: Japan Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Application

Table 29: Japan Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

Table 30: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Country

Table 31: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Platform

Table 32: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Product Type

Table 33: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Application

Table 34: Middle East & Africa Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

Table 35: Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Region

Table 36: Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Platform

Table 37: Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Product Type

Table 38: Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Application

Table 39: Global Biopharmaceutical Contract Manufacturing Market Size (US$ Mn) Analysis 2012–2016 and Forecast 2017–2027, By Therapeutic Area

"kindly copy the toc from our website
https://www.futuremarketinsights.com/reports/biopharmaceutical-contract-manufacturing-market/toc


【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ バイオ医薬品委託製造の世界市場分析(Biopharmaceutical Contract Manufacturing Market: Oncology Segment by Therapeutic Area to Dominate the Global Market Through 2027: Global Industry Analysis 2012–2016 and Opportunity Assessment 2017–2027)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆